These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 8578486)

  • 1. Effectiveness and safety of low molecular weight heparins (LMWH) in the prevention of venous thromboembolism (VTE).
    Kakkar VV
    Thromb Haemost; 1995 Jul; 74(1):364-8. PubMed ID: 8578486
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low molecular weight heparins: prophylaxis of venous thromboembolism in surgical patients.
    Kakkar VV
    Semin Hematol; 1997 Oct; 34(4 Suppl 4):9-19. PubMed ID: 9399405
    [No Abstract]   [Full Text] [Related]  

  • 3. Low molecular weight heparin for the out-of-hospital treatment of venous thrombosis: rationale and clinical results.
    Hirsh J; Crowther M
    Thromb Haemost; 1997 Jul; 78(1):689-92. PubMed ID: 9198240
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of the relative efficacy and safety of low molecular weight heparin and unfractionated heparin for the treatment of deep venous thrombosis.
    Hirsh J
    Semin Hematol; 1997 Oct; 34(4 Suppl 4):20-5. PubMed ID: 9399406
    [No Abstract]   [Full Text] [Related]  

  • 5. [Low-molecular-weight heparin in deep venous thrombosis. Dosage for all weight classes].
    MMW Fortschr Med; 2003 Jun; 145(24):56. PubMed ID: 12866309
    [No Abstract]   [Full Text] [Related]  

  • 6. Comparison of the relative efficacy and safety of low molecular weight heparin and unfractionated heparin for the treatment of venous thrombosis.
    Hirsh J
    Haemostasis; 1996 Oct; 26 Suppl 4():189-98. PubMed ID: 8979124
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low molecular weight versus unfractionated heparin. A clinical and economic appraisal.
    Heaton D; Pearce M
    Pharmacoeconomics; 1995 Aug; 8(2):91-9. PubMed ID: 10155614
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low molecular weight heparins (LMWH) in the treatment of patients with acute venous thromboembolism.
    Hirsh J; Siragusa S; Cosmi B; Ginsberg JS
    Thromb Haemost; 1995 Jul; 74(1):360-3. PubMed ID: 8578485
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Management of venous thromboembolism: optimization by clinical trials.
    Turpie AG
    Haemostasis; 1996 Oct; 26 Suppl 4():220-6. PubMed ID: 8979127
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk assessment and prophylaxis of venous thromboembolism in acutely and/or critically ill patients.
    Davidson BL
    Haemostasis; 2000; 30 Suppl 2():77-81; discussion 63. PubMed ID: 11251346
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Unfractionated and low-molecular-weight heparin. Comparisons and current recommendations.
    Pineo GF; Hull RD
    Med Clin North Am; 1998 May; 82(3):587-99. PubMed ID: 9646781
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low molecular weight heparin and unfractionated heparin for prevention of thrombo-embolism in general surgery: a meta-analysis of randomised clinical trials.
    Palmer AJ; Schramm W; Kirchhof B; Bergemann R
    Haemostasis; 1997; 27(2):65-74. PubMed ID: 9212354
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical potential of low molecular weight heparins.
    Messmore HL
    Semin Thromb Hemost; 1989 Oct; 15(4):405-8. PubMed ID: 2554501
    [No Abstract]   [Full Text] [Related]  

  • 14. Low-molecular-weight heparin for the out-of-hospital treatment of venous thrombosis: rationale and clinical results.
    Crowther M; Hirsh J
    Semin Thromb Hemost; 1997; 23(1):77-81. PubMed ID: 9156414
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [State of the art: low-molecular-weight heparin and beyond].
    Cimminiello C; Casali G; Vitali L
    Minerva Cardioangiol; 2000 Dec; 48(12 Suppl 1):61-5. PubMed ID: 11253343
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Should low-molecular-weight heparins replace unfractionated heparin as the agent of choice for adults with deep venous thrombosis?
    Brewer D
    J Fam Pract; 1998 Sep; 47(3):185-92. PubMed ID: 9752370
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A comparative double-blind, randomised trial of a new second generation LMWH (bemiparin) and UFH in the prevention of post-operative venous thromboembolism. The Bemiparin Assessment group.
    Kakkar VV; Howes J; Sharma V; Kadziola Z
    Thromb Haemost; 2000 Apr; 83(4):523-9. PubMed ID: 10780310
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low-molecular-weight heparin (LMWH) in the treatment of thrombosis.
    Holzheimer RG
    Eur J Med Res; 2004 Apr; 9(4):225-39. PubMed ID: 15210403
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Evidence-based guidelines for prevention and therapy of venous thromboembolism].
    Falciani M; Dilaghi B; Conti AA; Caciolli S; Gensini GF
    Minerva Cardioangiol; 2000 Dec; 48(12 Suppl 1):27-35. PubMed ID: 11253337
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low molecular weight heparin for the prevention and treatment of venous thromboembolism.
    Raskob GE
    Curr Opin Pulm Med; 1996 Jul; 2(4):305-10. PubMed ID: 9363157
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.